CLL Society ASH 2020 Day 4 Updates and Wrap-Up... - CLL Support

CLL Support

23,343 members40,054 posts

CLL Society ASH 2020 Day 4 Updates and Wrap-Up Less fun! No hugs. But we are leaving with a lot of treats!

bkoffman profile image
bkoffmanCLL CURE Hero
5 Replies

CLL Society ASH 2020 Day 4 Updates and Wrap-Up Dec. 8th was the 4th and final day of ASH 2020, the American Society of Hematology Annual meeting and Exposition. Less fun! No hugs. But we are leaving with a lot of treats and the promise of much more to come. Here is some of what I am taking away from ASH 2020.

We heard some compelling data on new generations of targeted drugs that are better tolerated such as experimental reversable BTKis that are active when CLL has stopped responding to the approved medications; a new PI3Ki with an improved safety profile; deeper ways to measure MRD which is being increasingly recognized as a powerful predictive tool for guiding therapy; dozens of combinations of experimental and approved novel agents, showing amazing results. 100% ORR (overall response rates) were not uncommon; research on predicting whose disease will be more aggressive & who will respond to a particular drug. Venetoclax: The boomerang drug! It seems there is life after progression on Venetoclax, as it sometimes works again when given a second chance!

We learned that CAR-T cells should soon have an important place in treating CLL. And we even heard that 2/3 patients with RT responded to a “fresh”, locally made, never frozen CAR-T product.

It wasn’t all good news: CLL patient meets COVID-19 is still bad news and that the new shingles vaccine may not have strong effect. And let’s not forget that we remain at higher risk for infections and second cancers. Outrageously, too many doctors are still not doing proper testing on their CLL patients and that too many are still using CIT (chemo-immuno-therapy) when it won’t work. Spread the word on our Test Before Treat™ and Expert Access Programs™ to empower patients to get the testing they need and a free expert second opinion!

Expect 100s of ZOOM interviews, videos, and written reports from this most important hematology meeting of the year over the next 12 months.

We are recognizing that, while the progress has been enormous, there is still much to be done. cllsociety.org/2020/12/ash-...

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
5 Replies
vepiskop profile image
vepiskop

Very informative summary Brian! Many thanks, stay safe. Vasso

Thank you for a uplifting finale!

Mystic75 profile image
Mystic75

How about a virtual hug! 🤗

Is there somewhere I can find more information on the reactivation of Venetoclax after resistance?

bkoffman profile image
bkoffmanCLL CURE Hero in reply toUniversallyPersonal

We will be posting my interview with Dr. Meghan Thompson on her ASH abstract, but you can read this in the meantime here: ash.confex.com/ash/2020/web... The poster is available too

Not what you're looking for?

You may also like...

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over...
lankisterguy profile image
Volunteer

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

Hi, Just back from a frenetic and fantastic ASH, but still have news to share from ASCO. But first...
bkoffman profile image
CLL CURE Hero

Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
lankisterguy profile image
Volunteer

Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021

17th Sept 21 "George Follows, a UK CLL expert, provides his thoughts on updated data from key...
Jm954 profile image
Administrator

My 1 year CAR-T anniversary and from ASH 2018, Dr. Siddiqi on how CLL treatment has changed.

Hi March 22, 2019 was my one year anniversary of receiving my experimental CAR-T cells in Seattle....
bkoffman profile image
CLL CURE Hero